Revolution Medicines, Inc.
HealthcareNASDAQ:RVMD · NASDAQ Global Select
+$4.64 today
Vol 1.58M · Avg 3.08M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-69.3%
avg -107.9%
ROIC
-56.8%
avg -74.0%
ROA
-48.0%
avg -46.7%
Analysis
ROA is currently the strongest return metric at -48.0% versus its period average of -46.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Mark A. Goldsmith | Chief Executive Officer, President & Chairman | $1.71M | — | 64 | $299,942.00 | 0.14% |
Stephen Kelsey Path. FRCP | President of Research & Development | $1.09M | — | 65 | $295,398.00 | 0.14% |
Margaret A. Horn | Chief Operating Officer | $1.02M | — | 63 | $157,570.00 | 0.07% |
Jack Anders | Chief Financial Officer | $874,133.00 | — | 49 | $125,512.00 | 0.06% |
Jeff Cislini | Senior Vice President, General Counsel & Corporate Secretary | $791,750.00 | — | 51 | $58,518.00 | 0.03% |
Xiaolin Wang | Executive Vice President of Development | $701,200.00 | — | 56 | $116,063.00 | 0.05% |
Gerwin Winter | Senior VP & GM for the European region | — | — | — | — | — |
Erin Graves | Senior Director of Corporate Communications & Investor Relations | — | — | — | — | — |
Zhengping Wang | Senior VP of Non-Clinical Development & Clinical Pharmacology | — | — | — | $116,063.00 | 0.05% |
Hieu Le | Vice President of Compliance | — | — | — | — | — |
Ryan Asay | Senior Vice President of Corporate Affairs | — | — | — | — | — |
Carlos Escobar | VP & Head of Information Security | — | — | — | — | — |
Martin D. Burke | Co-Founder & Chairman of Scientific Advisory Board | — | — | — | — | — |
Adrian Gill | Executive VP & Head of Early Discovery | — | — | — | — | — |
Anthony Mancini | Chief Global Commercialization Officer | — | — | 55 | $54,821.00 | 0.03% |
Kevan Shokat | Academic Co-Founder & Member of Scientific Advisory Board | — | — | — | — | — |
Alan Bart Sandler | Chief Development Officer | — | — | 69 | $0.00 | <0.01% |
Michael A. Fischbach | Academic Co-Founder & Member of Scientific Advisory Board | — | — | 45 | $295,398.00 | 0.14% |
Jan Smith | Chief Scientific Officer | — | — | — | — | — |
Walter Reiher | Chief Information Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
72
$61.33M
Net Sentiment
$61.33M
Net selling
Most Active
GOLDSMITH MARK A
23 transactions
1–10 of 72
Analysis
Insiders reported 0 buys worth $0.00 and 72 sells worth $61.33M over the last 12 months. That adds up to net selling of $61.33M. GOLDSMITH MARK A was the most active insider with 23 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A6 analysts |
| Revenue | N/A | N/A | +13.4% | +79.0% (9yr)7 analysts |
| Net Income | N/A | N/A | N/A | N/A7 analysts |
| EBIT | N/A | N/A | N/A | N/A7 analysts |
Analysis
Recent growth has been strongest in Revenue at +13.4% over three years. Forward estimates point to Revenue at +79.0% (9yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Roivant Sciences Ltd.
NASDAQ:ROIV
$21.61B
Moderna, Inc.
NASDAQ:MRNA
$19.80B
Ascendis Pharma A/S
NASDAQ:ASND
$13.47B
Exelixis, Inc.
NASDAQ:EXEL
$13.35B
BridgeBio Pharma, Inc.
NASDAQ:BBIO
$13.08B
Ionis Pharmaceuticals, Inc.
NASDAQ:IONS
$12.11B
Madrigal Pharmaceuticals, Inc.
NASDAQ:MDGL
$11.08B
Summit Therapeutics Inc.
NASDAQ:SMMT
$10.86B
BioMarin Pharmaceutical Inc.
NASDAQ:BMRN
$10.81B
Atrium Therapeutics, Inc.
NASDAQ:RNA
$211.60M
Who manages RVMD?
Revolution Medicines, Inc. (RVMD) lists 20 active executives. The top listed executive is Jack Anders, Chief Financial Officer.
Are RVMD insiders buying or selling?
Recent insider activity shows net buying of $71.03M.
Explore More
Continue the stock analysis
Jump to another research area for this company.